















COBAPHARMA API




Link to success




PRODUCTS

Product	Therapeutic Use	Regulatory Status	
		DMF	CEP
Allopurinol	Antigout	✓	
Apixaban	Anticoagulant	✓	
Atorvastatin	Cholesterol	✓	
Azithromycin	Antibiotic	✓	
Ciprofloxacin	Antibiotic	✓	
Clarithromycin	Antibiotic	✓	
Colistimethate Sodium	Antibiotic	✓	
Donepezil	Central nervous	✓	Filed
Ezetimibe	Antihyperlipidemic	✓	
Glycopyrronium Bromide	Bronchodilator (COPD)	✓	
Lacosamide	Antiepileptic	✓	
Mirabegron	Overactive bladder	✓	
Naproxen	Anti-inflammatory	✓	
Omeprazole	Antiulcerative	✓	
Rivaroxaban	Anticoagulant	✓	Filed
Rosuvastatin	Antihyperlipidemic	✓	
Sacubitril Sodium	Heart Failure	✓	
Solifenacin	Overactive bladder	✓	
Ticagrelor	Platelet aggregation inhibitor	✓	Filed

ANTIHYPERTENSIVE

Product	Therapeutic Use	Regulatory Status	
		DMF	CEP
Candesartan	Hypertension	✓	
Irbesartan	Hypertension	✓	
Olmesartan	Hypertension	✓	
Sacubitril / Valsartan	Hypertension	✓	

ANTIDIABETIC

Product	Therapeutic Use	Regulatory Status	
		DMF	CEP
Canagliflozin	Diabetes	✓	
Dapagliflozin	Diabetes	✓	
Empagliflozin	Diabetes	✓	
Linagliptin	Diabetes	✓	
Sitagliptin	Diabetes	✓	
Vildagliptin	Diabetes	✓	

None of the products will be offered / supplied to countries in which this could be in conflict with existing patents. However, the final responsibility lies exclusively with the buyer. Patented products available for R&D use as permitted under 35 USC 271 (e) (1).

CONTROLLED SUBSTANCES

Product	Therapeutic Use	Regulatory Status	
		DMF	CEP
Methadone	Opioid dependence	✓	🇪🇺
Methylphenidate	Central nervous	✓	🇪🇺
Phenobarbital	Anticonvulsant	✓	🇪🇺

CEPHALOSPORINS

Product	Therapeutic Use	Regulatory Status	
		DMF	CEP
Cefazolin Sodium	Antibiotic	✓	🇪🇺
Cefepime Dihydrochloride	Antibiotic	✓	🇪🇺
Cefixime	Antibiotic	✓	🇪🇺
Ceftazidime	Antibiotic	✓	🇪🇺
Cefotaxime Sodium	Antibiotic	✓	🇪🇺
Ceftriaxone Sodium	Antibiotic	✓	🇪🇺
Cefuroxime Sodium	Antibiotic	✓	🇪🇺

UNDER DEVELOPMENT PRODUCTS

Product	Therapeutic Use	Regulatory Status
		DMF
Alogliptin	Anti-diabetic	Q4 2021
Baloxavir	Influenza	Q1 2022
Betrixaban	Venous Thromboembolism	Q1 2022
Bictegravir	HIV-1 Infection	Q1 2022
Edoxaban	Anticoagulant	Q3 2021
Elagolix	Endometriosis	Q4 2021
Eltrombopag	ITP & Aplastic Anemia	Q2 2022
Niraparib	Primary Peritoneal Cancer	Q1 2022
Regadenoson	Myocardial perfusion	Q4 2021
Teriflunomide	Multiple sclerosis	Q1 2022
Venetoclax	CLL	Q1 2022
Vortioxetine	Depression	Q3 2021

None of the products will be offered / supplied to countries in which this could be in conflict with existing patents. However, the final responsibility lies exclusively with the buyer. Patented products available for R&D use as permitted under 35 USC 271 (e) (1).



COBAPHARMA

C/ Rosselló, 34, 1º 2ª
08029, Barcelona, Spain
Tel: +34 93 355 49 15
www.cobapharma.com



Certificate Number
CERT7205CBPEB

